Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Accumulated Expenses (2016 - 2020)

Medifast (MED) has disclosed Accumulated Expenses for 7 consecutive years, with $22.6 million as the latest value for Q4 2020.

  • For the quarter ending Q4 2020, Accumulated Expenses rose 117.1% year-over-year to $22.6 million, compared with a TTM value of $22.6 million through Dec 2020, up 117.1%, and an annual FY2020 reading of $22.6 million, up 117.1% over the prior year.
  • Accumulated Expenses was $22.6 million for Q4 2020 at Medifast, up from $10.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $22.6 million in Q4 2020 and bottomed at $301000.0 in Q3 2016.
  • Average Accumulated Expenses over 5 years is $8.4 million, with a median of $6.1 million recorded in 2017.
  • The sharpest move saw Accumulated Expenses soared 321.35% in 2016, then dropped 15.77% in 2018.
  • Year by year, Accumulated Expenses stood at $4.8 million in 2016, then surged by 38.41% to $6.6 million in 2017, then decreased by 15.77% to $5.5 million in 2018, then soared by 87.68% to $10.4 million in 2019, then skyrocketed by 117.1% to $22.6 million in 2020.
  • Business Quant data shows Accumulated Expenses for MED at $22.6 million in Q4 2020, $10.4 million in Q4 2019, and $5.5 million in Q4 2018.